Vertero
Financial Services · Biotechnology
Overview
Breaking Barriers in Neurodegenerative Disease Treatment. At Vertero, our mission is to change the perception and treatment of neurodegenerative diseases to delay disease progression and preserve quality of life for patients as long as possible.
Official records
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Taiho VenturesVia a fund
University of Tokyo Innovation PlatformVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Vertero Advances into Phase 1b Study with VT-5006 for the Treatment of Parkinson's Disease
First participant with Parkinson's disease dosed at the Centre for Human Drug Research in the NetherlandsWOBURN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative di
Read more
Report
Vertero lance une étude de phase 1b pour le VT-5006 dans le traitement de la maladie de Parkinson
Read more
Report
Vertero Advances Into Phase 1B Study With VT-5006 For The Treatment Of Parkinson
Vertero Advances Into Phase 1B Study With VT-5006 For The Treatment Of Parkinson
Read more
Report
Vertero Strengthens Board Of Directors With Appointment Of Independent Chair R. Scott Greer
Vertero Strengthens Board Of Directors With Appointment Of Independent Chair R. Scott Greer. Biotech veteran to join Vertero as the company accelerates development momentum in neurodegenerative diseaseWOBURN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Verte
Read more
Report
Vertero Appoints Jeffrey Kasten as Chief Business Officer
Life sciences veteran joins Vertero's executive leadership team to drive strategic partnerships and accelerate portfolio strategy in neurodegenerative disease
Read more
Report
Vertero Appoints Jeffrey Kasten as Chief Business Officer
Life sciences veteran joins Vertero's executive leadership team to drive strategic partnerships and accelerate portfolio strategy in neurodegenerative diseaseWOBURN, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Vertero Therapeutics, a clinical-stage biotechno
Read more
Report
Vertero Unveils New Strategic Direction Focused on Breaking Barriers in Neurodegenerative Diseases
Formerly Axial Therapeutics, Vertero is rapidly advancing a novel approach to address peripheral drivers of challenging neurodegenerative diseases
Read more
Report